<div id="readability-page-1"><p>Truist Financial Corp reduced its position in shares of  Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,193 shares of the biopharmaceutical company's stock after selling 59,003 shares during the period. Truist Financial Corp owned 0.16% of Emergent BioSolutions worth $814,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Emergent BioSolutions</strong> alerts:</span></p></div><ul><li>Watch These 4 Overbought Stocks As Market Rotation Continues</li></ul><p>Other hedge funds also recently modified their holdings of the company. Stifel Financial Corp purchased a new position in shares of  Emergent BioSolutions during the 3rd quarter worth about $96,000.  FORA Capital LLC purchased a new position in shares of  Emergent BioSolutions during the 3rd quarter worth about $103,000.  Landscape Capital Management L.L.C. purchased a new position in shares of  Emergent BioSolutions during the 3rd quarter worth about $141,000.  Entropy Technologies LP purchased a new position in shares of  Emergent BioSolutions during the 3rd quarter worth about $155,000.  Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of  Emergent BioSolutions during the 3rd quarter worth about $295,000. 78.40% of the stock is owned by institutional investors and hedge funds. </p><h2>Emergent BioSolutions Stock Performance</h2><p>Emergent BioSolutions stock opened at $7.46 on Friday. The company has a market cap of $403.94 million, a PE ratio of -1.82 and a beta of 1.62. The company has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $9.06. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10. </p><h2>Wall Street Analyst Weigh In</h2><p>EBS has been the topic of several research reports. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, February 17th. Finally, HC Wainwright  restated a &#34;buy&#34; rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, January 21st.</p><p><b>Check Out Our Latest Stock Analysis on Emergent BioSolutions</b></p><h2>Emergent BioSolutions Profile</h2> (Free Report)<p>Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Emergent BioSolutions</li><li>How to buy stock: A step-by-step guide for beginners </li><li>Autodesk Designs Value for Investors: Uptrend Set to Continue</li><li>3 Ways To Invest In Coffee, Other Than Drinking It</li><li>Anheuser-Busch Stock Rallies—Is the King of Beers Back?</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>MarketBeat Week in Review – 02/24 - 02/28</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Emergent BioSolutions Right Now?</h2><p>Before you consider Emergent BioSolutions, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.</p><p>While Emergent BioSolutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Truist Financial Corp reduced its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 40.9% in Q4, owning 85,193 shares after selling 59,003. The company is valued at $814,000. Other hedge funds also increased their positions. Emergent's stock opened at $7.46, with a market cap of $403.94 million and a PE ratio of -1.82. Analysts have raised price targets, with Benchmark increasing it from $8.00 to $12.00, maintaining a "buy" rating.</p>

Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Truist Financial Corp